AusperBio secures USD 37Mln in series A financing
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, with the goal of achieving functional cure for chronic hepatitis B (CHB) infection, yesterday announced the completion of a $37 million Series A financing round. This round was led by existing investor, InnoPinnacle Fund, with participation from new […]
